Pharmacokinetics (PK)
Integrated PK Services for Complex Drug Development in NHPs
At Envol Biomedical, we specialize in conducting robust pharmacokinetic (PK) studies in nonhuman primates (NHPs) to help sponsors understand how their investigational therapies behave in the body. Whether you're developing a small molecule, biologic, or genetic therapeutic, we deliver high-quality PK data with unmatched responsiveness, surgical expertise, and end-to-end technical integration.
From precise surgical dosing to real-time PK modeling with Resero, Envol ensures your team receives the data you need—accurately, efficiently, and ready for decision-making.
Input your text here! The text element is intended for longform copy that could potentially include multiple paragraphs.
What Is Pharmacokinetics?
Pharmacokinetics is the study of what the body does to a drug—how it is absorbed, distributed, metabolized, and excreted (ADME). In short:
Where does the drug go? How long does it stay there?
At Envol, we approach PK as more than just sample collection and analysis. We build integrated study frameworks that reflect:
- The complexity of your molecule
- The route and method of administration
- The biological system under study
- Regulatory alignment with IND/GLP expectations
How We Conduct PK Studies at Envol
Our PK platform is supported by a set of core competencies that set Envol apart:
Surgical Expertise for Serial Sampling
NHP studies demand surgical sophistication. Our in-house team performs:
- Vascular access port placement
- Serial blood sampling techniques
- Targeted dosing routes, including intrathecal, intracisternal, intranasal, CNS, subcutaneous, and intravenous
These techniques reduce animal use while increasing data continuity—critical for high-resolution PK profiles.
Dosing Capabilities Built for Flexibility
We support a wide range of administration methods, enabling studies that explore:
- Acute and chronic dosing
- Complex delivery routes for gene therapies and ASOs
- Specialized delivery technologies such as lipid nanoparticles (LNPs) or viral vectors
Resero-Powered PK Modeling and Reporting
Through our partnership with Resero, Envol provides:
- Sophisticated PK and TK modeling tools
- Instantaneous visualizations and reporting
- Seamless integration of bioanalytical data into regulatory-ready outputs
With Resero’s proprietary platform, we cut weeks or months off timelines, empowering sponsors to make informed decisions faster.
Supporting Infrastructure: Built for Quality
Our PK studies are supported by:
- A fully integrated Core Laboratory offering formulation support, immunoassays, ELISAs, ligand-binding assays, and PCR/ddPCR
- Access to vertically integrated NHP resources, including multiple age and sex cohorts
- A customer service-oriented culture, where responsiveness and transparency are standard
All of this is embedded within a GLP-compliant environment with SEND compatibility, LIMS integration, and regulatory foresight.
Why Sponsors Choose Envol for PK Studies
Here are a few key reasons sponsors choose Envol:
- Surgical precision + flexible dosing
- Real-time PK modeling with Resero
- GLP and non-GLP study design and execution
- Disease model integration
- Faster reporting, better insights
Whether you're modeling the pharmacokinetics of an mRNA therapeutic, evaluating tissue exposure in a new indication, or preparing for a pre-IND meeting, Envol has the tools and expertise to help you move forward with confidence.
Study Designs for All Program Types
Our PK services are tailored to meet the needs of early discovery, translational pharmacology, and IND-enabling programs.
We regularly support:
- Healthy NHP pharmacokinetics
- PK studies within disease-specific models (e.g., metabolic, CNS, respiratory)
- Combination PK/PD studies
- GLP and non-GLP studies with validated reporting
We understand that pharmacokinetics is often a critical gating item for IND success, and we align our execution accordingly.
Recent Blogs
The Evolution of Primate Supply Chains: Envol Biomedical’s Jake McDonald to Present at ACT 2025
As one of the nation’s leading GLP toxicology partners, Envol Biomedical is proud to be...Advancing CNS Drug Development: Envol Biomedical to Debut First-in-Kind NHP COFM Capabilities at ACT 2025
As one of the nation’s leading GLP toxicology partners and the largest provider of NHP...The Ripple Effects of Uncertainty Around FDA Changes: Envol Biomedical and White Oak Regulatory Tox Present at ACT 2025
Few years in recent memory have tested the clarity and consistency of the FDA’s regulatory...Let’s Build Your PK Program
Tell us about your therapeutic and we’ll design a smart, scalable PK strategy to support it.